American Association for Clinical Chemistry - Atlanta, GA-July, 2011

	PGx Testing for Predicting Statin-Induced Myalgia Alan Wu, Ph.D. - Chief of Clinical Chemistry and Toxicology Laboratories at San Francisco Hospital. Chief of the Clinical Pharmacogenomics Laboratory, University of California San Francisco.
	Emerging Growth in PGx and Women’s Health Testing in a Reference Lab Beau Fessenden – CEO, President of Natural Molecular Testing Corp.
	Prescribing Clopidogrel based on CYP2C19 Genetic Testing Eugenio H. Zabaleta, P.h.D. – Clinical Chemist, MedCentral Health System
	Personalized Management of Psychiatric Drugs: Real-time Practice of DNA-Guided Drug Prescription at Hartford Hospital and Connecticut Gualberto Ruano – Director of Genetics Research at Hartford Hospital. President of Genomas.
	PGx Markers for Implementation in the Clinical Lab Gwen McMillin – P.h.D., DABCC (CC,TC), University of Utah/ARUP Laboratories
	Respiratory Viruses and S. Pneumoniae Identification Prof. Jacques Corbeil – Canada Research Chair in Medical Genomics. Department of Molecular Medicine, Université Laval
	Overview of Cancer Signaling Pathways Patrick J Dillion, P.h. D. – Vice President of Research and Development, AutoGenomics, Inc.
	Challenges of Making an Accurate Diagnosis in Vaginitis/Vaginosis Robert B. Cole, M.D., F.A.C.O.G. – Chief Medical Officer, AutoGenomics, Inc.
	Available Assays for Diagnosis and Management of Vaginitis Sajo Beqaj, P.h.D., HCLD, CC (ABB) – Pathology, Inc.
	K-ras Mutation Analysis and Companion Diagnostic Testing – An Overview Ted E. Schutzbank, P.h.D., D (ABMM) – Associate Director of Genomics, Covance Central Laboratory Services
	Dynamic Opportunities in Women’s Health Testing William Miller, HTL. MBA – CEO, AIBioTech